New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 7, 2014
13:55 EDTTEVA, RDYTeva won't be meaningfully hurt soon by new Copaxone filing, says BMO Capital
After Teva (TEVA) confirmed that it received the first paragraph IV notice for the 3x per week version of its Copaxone drug from Dr. Reddy's (RDY), BMO Capital said it had expected companies to seek to market a generic version of the latest Copaxone formulation, but was surprised that Dr. Reddy's took this action. The firm notes that Teva's decision to file a lawsuit against Dr. Reddy over the application will trigger a 30 month stay of approval of the generic version,. BMIO Capital says that investors should keep this issue on their radar, but the firm does not expect Teva to be meaningfully hurt in the near-term by this development. It keeps an Outperform rating on Teva.
News For TEVA;RDY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
09:11 EDTTEVATeva reported great Q3 results, says BMO Capital
Subscribe for More Information
09:06 EDTTEVATeva says assessing M&A opportunities of all sizes
08:49 EDTTEVATeva says may pursue generic businesses in emerging markets
Says not ruling out "transformational" transactions. Says open to specialty assets in U.S., Europe.
08:40 EDTTEVATeva says $5.00-$5.10 FY14 EPS guidance is for exclusive Copaxone scenario
Subscribe for More Information
07:06 EDTTEVATeva board authorizes increase in share repurchase program to $3B
The Company announced today that, as authorized by the Board of Directors, it will increase its share repurchase program by $1.7 billion to $3 billion. The program has no time limitations. The Company intends to begin purchasing shares promptly.
07:05 EDTTEVATeva raises FY14 EPS view to $5.00-$5.10 from $4.90-$5.10
Subscribe for More Information
07:05 EDTTEVATeva reports Q3 EPS $1.32, consensus $1.23
Subscribe for More Information
October 29, 2014
06:46 EDTRDYDr. Reddy's Labs reports Q2 EPS 54c vs. 65c a year ago
Reports Q2 revenue $579M vs. $542M a year ago.
October 28, 2014
13:26 EDTRDYDr. Reddy's Labs announces launch of Sirolimus Tablets
Subscribe for More Information
October 27, 2014
07:22 EDTTEVAAmerican College of Chest Physicians to hold a conference
Subscribe for More Information
October 20, 2014
06:28 EDTTEVAAllergan price target raised to $210 from $190 at Citigroup
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use